N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-morpholinobenzamide | 1616961-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-morpholinobenzamide
• 英文别名: N-[2-(2-methyl-1H-indol-3-yl)ethyl]-4-morpholin-4-ylbenzamide
• CAS: 1616961-21-7
• 化学式: C₂₂H₂₅N₃O₂
• 分子量: 363.459
• InChiKey: DWJLFCGMQDOLPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1H-2-甲基-3-氨乙基吲哚 、 4-吗啉基苯甲酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-morpholinobenzamide
  参考文献：
  名称：

  Development of second generation EP2 antagonists with high selectivity

  摘要：

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.076

文献信息

• [EN] PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR EP2 DE LA PROSTAGLANDINE, DÉRIVÉS, ET UTILISATIONS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2020191208A1

  公开（公告）日：2020-09-24

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  该公开涉及前列腺素受体EP2拮抗剂、衍生物、组合物以及相关方法。在某些实施方式中，该公开涉及治疗或预防EP2受体激活在生理角色中发挥作用的疾病和情况的方法，例如但不限于脑损伤、炎症性疾病、癫痫、癫痫后的神经炎症、疼痛、子宫内膜异位症、癌症、类风湿性关节炎、皮肤炎症、血管炎症、结肠炎和神经系统疾病，通过向需要的受试者施用含有本文所披露的化合物的药物组合物。
• PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO
  申请人：Emory University

  公开号：US20220162186A1

  公开（公告）日：2022-05-26

  The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.